These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 26611771)
1. The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Shoaibi A; Rao GA; Cai B; Rawl J; Hébert JR Ann Epidemiol; 2016 Jan; 26(1):36-42.e1-2. PubMed ID: 26611771 [TBL] [Abstract][Full Text] [Related]
2. Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer. Shoaibi A; Rao GA; Cai B; Rawl J; Haddock KS; Hébert JR Prostate; 2017 Feb; 77(2):173-184. PubMed ID: 27699819 [TBL] [Abstract][Full Text] [Related]
3. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O'Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; Brady AF; van Os T; Gallagher D; Johannsson O; Donaldson A; Barwell J; Nicolai N; Friedman E; Obeid E; Greenhalgh L; Murthy V; Copakova L; Saya S; McGrath J; Cooke P; Rønlund K; Richardson K; Henderson A; Teo SH; Arun B; Kast K; Dias A; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Eccles DM; Tricker K; Eyfjord J; Falconer A; Foster C; Gronberg H; Hamdy FC; Stefansdottir V; Khoo V; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra A; Moynihan C; Rennert G; Suri M; Wilson P; Dudderidge T; ; Offman J; Kote-Jarai Z; Vickers A; Lilja H; Eeles RA Eur Urol; 2019 Dec; 76(6):831-842. PubMed ID: 31537406 [TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981 [TBL] [Abstract][Full Text] [Related]
5. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer. Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831 [TBL] [Abstract][Full Text] [Related]
6. Variation of Prostate-specific Antigen Value in Men and Risk of High-grade Prostate Cancer: Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Study. Boniol M; Autier P; Perrin P; Boyle P Urology; 2015 May; 85(5):1117-1122. PubMed ID: 25917734 [TBL] [Abstract][Full Text] [Related]
7. The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. Castro E; Mikropoulos C; Bancroft EK; Dadaev T; Goh C; Taylor N; Saunders E; Borley N; Keating D; Page EC; Saya S; Hazell S; Livni N; deSouza N; Neal D; Hamdy FC; Kumar P; Antoniou AC; Kote-Jarai Z; ; Eeles RA Oncologist; 2016 Jun; 21(6):716-22. PubMed ID: 27151655 [TBL] [Abstract][Full Text] [Related]
8. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. Gann PH; Hennekens CH; Stampfer MJ JAMA; 1995 Jan; 273(4):289-94. PubMed ID: 7529341 [TBL] [Abstract][Full Text] [Related]
9. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. Candas B; Labrie F; Gomez JL; Cusan L; Chevrette E; Lévesque J; Brousseau G J Urol; 2006 Feb; 175(2):510-6; discussion 516-7. PubMed ID: 16406983 [TBL] [Abstract][Full Text] [Related]
10. Plasma carotenoids and tocopherols in relation to prostate-specific antigen (PSA) levels among men with biochemical recurrence of prostate cancer. Antwi SO; Steck SE; Zhang H; Stumm L; Zhang J; Hurley TG; Hebert JR Cancer Epidemiol; 2015 Oct; 39(5):752-62. PubMed ID: 26165176 [TBL] [Abstract][Full Text] [Related]
11. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL. Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057 [TBL] [Abstract][Full Text] [Related]
12. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635 [TBL] [Abstract][Full Text] [Related]
13. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. D'Amico AV; Renshaw AA; Sussman B; Chen MH JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650 [TBL] [Abstract][Full Text] [Related]
14. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332 [TBL] [Abstract][Full Text] [Related]
15. Prostate specific antigen density of the transition zone for early detection of prostate cancer. Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889 [TBL] [Abstract][Full Text] [Related]
16. [Clinical value of prostate specific antigen screening in early detection of prostate cancer]. Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870 [TBL] [Abstract][Full Text] [Related]
17. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Grubb RL; Black A; Izmirlian G; Hickey TP; Pinsky PF; Mabie JE; Riley TL; Ragard LR; Prorok PC; Berg CD; Crawford ED; Church TR; Andriole GL; Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):748-51. PubMed ID: 19258472 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients. Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025 [TBL] [Abstract][Full Text] [Related]